1 / 49

Program Goals

Pioneering the Future: Innovations and Strategies for Preventing Chemotherapy-Induced Nausea and Vomiting. Program Goals. The Importance of Controlling Nausea and Vomiting in the Setting of Chemotherapy. CINV: Consequences. Emetogenicity of IV Chemotherapy. Emetogenicity of Oral Chemotherapy.

eli
Download Presentation

Program Goals

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Pioneering the Future: Innovations and Strategies for Preventing Chemotherapy-Induced Nausea and Vomiting

  2. Program Goals

  3. The Importance of Controlling Nausea and Vomiting in the Setting of Chemotherapy

  4. CINV: Consequences

  5. Emetogenicity of IV Chemotherapy

  6. Emetogenicity of Oral Chemotherapy

  7. Types of CINV

  8. Neurotransmitters Involved in Emesis

  9. Major Classes of Antiemetic Agents: Definitions

  10. Pharmacokinetic and Physiological Differences Among 5-HT3 RAs

  11. CINV Clinical Practice GuidelinesRecommendations and Related Evidence

  12. HEC: Guideline Recommendations

  13. Olanzapine + PALO + DEX vs APR + PALO + DEX: Efficacy

  14. Olanzapine + PALO + DEX vs APR + PALO + DEX: Safety

  15. MEC: Guideline Recommendations

  16. PALO + DEX vs GRN + DEX in Chemotherapy-Naive Patients Receiving Cisplatin (≥ 50 mg/m2) or AC-Based Chemotherapy

  17. Gaps/Goals: MEC and HEC Settings

  18. Should DEX be Administered on Days 1-3 or Day 1 Only When Given in Combination With PALO?

  19. Assessing the Efficacy of Single-dose DEX in Chemotherapy-Naive Patients Receiving AC-Based Chemotherapy

  20. Steroid Sparing in Non-AC MEC: Efficacy

  21. Steroid Sparing in Non-AC MEC: Treatment-Related AEs

  22. Emerging Treatments for Preventing CINV

  23. 5-HT3 RAs

  24. NK-1 RAs: Available Formulations

  25. Investigational NK-1 RAs

  26. Phase 2 Trial: Rolapitant (200 mg oral) + OND + DEX in Chemotherapy-Naive Patients Receiving HEC

  27. Oral NEPA + Oral DEX vs Oral PALO + Oral DEX in AC-Based MEC: Multinational, Randomized, Double-Blind Phase 3 Study

  28. NEPA + DEX vs PALO + DEX in AC-Based MEC: Efficacy Outcomes

  29. NEPA + DEX vs PALO + DEX in AC-Based MEC: Safety

  30. NEPA: Phase 2 Netupitant Dose-Finding StudyStudy Design

  31. NEPA: Phase 2 Netupitant Dose-Finding StudyOverall CR Rates

  32. NEPA: Phase 2 TrialSecondary Efficacy Endpoints

  33. NEPA in Multicycle MEC and HEC: Multicenter, Randomized, Double-blind, Phase 3 Study

  34. NEPA in Multicycle MEC and HEC: Overall CR Rates

  35. NEPA in Multicycle MEC and HEC: Most Common AEs

  36. Innovations and Strategies in the Prevention of CINV: Summary

  37. Abbreviations

  38. Abbreviations (cont)

  39. References

  40. References (cont)

  41. References (cont)

  42. References (cont)

  43. References (cont)

  44. References (cont)

  45. References (cont)

  46. References (cont)

  47. References (cont)

More Related